DailyIQ
|
Sector:HealthcareAll sectors
Last updated 7 minutes ago

BMY·Bristol-Myers Squibb Company

$.
-. (-.%)
After Hours
High
$58.80
Open
$58.03
Market Cap
118.50B
52W High
$62.89
Low
$57.13
P. Close
$57.53
P/E
19.83
52W Low
$42.52
Fwd P/E
9.40
Mean Target
$62.96
Technical Score (1D)
23
SELL
News Sentiment
60
BULLISH
Bristol Myers Squibb will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, with a fireside chat at 2:00 p.m. ET. This event provides an opportunity for the company to share updates with the investment community. Earlier, BMY was set to present extensive new clinical data at the ASCO Annual Meeting, featuring over 60 scientific disclosures including late-breaking Phase 3 data for mezigdomide and izalontamab brengitecan. These presentations cover a range of cancers, offering investors a detailed look at the company's oncology pipeline. In other news, Janux Therapeutics has expanded collaborations, including a notable partnership with BMY, signaling potential for synergistic development in the immuno-oncology space. Investors should monitor clinical trial progress from these collaborations. Separately, BMY is identified as a strong value stock, supported by favorable financial metrics and market position, suggesting potential upside driven by fundamental strengths. However, the company faces a significant patent cliff for Eliquis, projected to cause substantial revenue declines of $14.2 billion over six years, highlighting the rapid erosion of brand value with generic competition. Investors should monitor BMY's strategic response to this challenge.
Earnings Summary
Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines across oncology, hematology, immunology, and cardiovascular diseases. Operating within the Drug Manufacturers - General industry in the Healthcare sector, the company's portfolio includes key treatments like Eliquis and Opdivo, aimed at addressing significant unmet medical needs worldwide. The company's performance over the last few quarters shows a mixed trend in earnings per share (EPS) against analyst estimates. In Q4 2025, BMY reported EPS of $1.26, exceeding the estimate of $1.1262, and in Q1 2026, EPS was $1.58, surpassing the estimate of $1.42158. However, revenue figures for Q4 2025 ($12.502 billion) and Q1 2026 ($11.489 billion) showed growth compared to estimates, indicating a positive revenue trend. Looking at the historical streak, Bristol-Myers Squibb has demonstrated an ability to beat EPS estimates in recent quarters, such as Q4 2025 and Q1 2026, suggesting a potential turnaround or stabilization after a period of stagnation. The company has also shown revenue growth in the most recent reported quarters, which is a positive indicator for its operational performance. Recent news highlights significant strategic moves by Bristol-Myers Squibb, including a major collaboration with Hengrui Pharma focused on 13 early-stage oncology, hematology, and immunology programs to bolster its future drug pipeline. Additionally, the company is expanding its partnership with Tempus AI, leveraging artificial intelligence and real-world data to optimize clinical trial designs, particularly in oncology and neuroscience, aiming to improve the Probability of Technical & Regulatory Success (PTRS). These collaborations signal a forward-looking approach to drug development and pipeline enhancement. Investors will be watching for the impact of these strategic collaborations on future earnings and the success of the company's pipeline development in the upcoming quarters, particularly how the AI integration influences trial outcomes and regulatory approvals.

EPS

EstBeatMiss
$1.00$1.22$1.45$1.68$1.90Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.61 - -
Q1'26$1.42$1.58+11.1%
Q4'25$1.13$1.26+11.9%
Q3'25$1.52$1.63+7.6%
Q2'25$1.10$1.46+32.6%
Q1'25$1.50$1.80+19.9%

Revenue

EstBeatMiss
$10.7B$11.2B$11.7B$12.2B$12.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$11.8B - -
Q1'26$10.9B$11.5B+5.2%
Q4'25$12.4B$12.5B+0.8%
Q3'25 - $12.2B -
Q2'25 - $12.3B -
Q1'25 - $11.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BMY Stock Snapshot

BMY is currently trading at $57.55, giving Bristol-Myers Squibb Company a market cap of 118.50B and a P/E ratio of 19.8. Today's range spans $57.13–$58.80, with shares opening at $58.03 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 60/100.

Over the past year BMY has traded between $42.52 and $62.89 - the current price is +35.3% off the 52-week low and -8.5% from the high. 37 analysts cover the stock with a Hold consensus and a mean 12-month target of $62.96 (range $40.00–$75.00), implying upside of +9.4%.

Factor models are actively underweighting BMY: large-cap, Healthcare, 118.50B market cap, 23/100 (SELL), bullish sentiment (60/100). Price: $57.55 (in the upper portion of its 52-week range). (P/E: 19.8) Momentum and trend-following strategies reduce exposure when scores drop below the 23/100 threshold; quality factors recalibrate; low-vol strategies find better risk-adjusted alternatives elsewhere in the sector. Annual range: $42.52–$62.89. The systematic de-risking compounds the fundamental concern.

When a large-cap Healthcare name with 118.50B in capitalization prints a SELL signal (23/100) alongside bullish news sentiment (60/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $57.55 (in the upper portion of its 52-week range in the $42.52–$62.89 range), the structural support levels are where that sponsorship question gets answered.